Among the patients with diffuse large B-cell lymphoma receiving CD19 chimeric antigen receptor (CAR) therapy, those with Mut p53 have poorer overall survival rates than those with WT p53; therefore, TP53 is a valuable prognostic biomarker [94]. The gene discussed is TP53; the disease is diffuse large B-cell lymphoma.